Experienced in Gastrostomy

Dr. Maria Q. Baggstrom

Oncology
Washington University
10 Barnes W Dr, 200 Asthma And Allergy Cente, 
St Louis, MO 
Accepting New Patients
Experienced in Gastrostomy
Washington University
10 Barnes W Dr, 200 Asthma And Allergy Cente, 
St Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Maria Baggstrom is an Oncologist in St Louis, Missouri. Dr. Baggstrom is rated as an Experienced provider by MediFind in Gastrostomy. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Gastrostomy, and Bone Marrow Aspiration. Dr. Baggstrom is currently accepting new patients.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
10 Barnes W Dr, 200 Asthma And Allergy Cente, St Louis, MO 63141
Other Locations
WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Vorolanib, Atezolizumab
Study Phase: Phase 2
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Phase II Study of a Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Neoantigen DNA Vaccine, Durvalumab
Study Phase: Phase 2
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Allopurinol, Irinotecan
Study Phase: Phase 1
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
A Single-Arm Phase II Study With a Safety Lead-in of Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug, Device, Biological, Radiation
Study Drugs: Paclitaxel, Carboplatin AUC, Durvalumab
Study Phase: Phase 2
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Enrollment Status: Completed
Publish Date: July 30, 2024
Intervention Type: Drug, Procedure
Study Drugs: Ramucirumab, Atezolizumab
Study Phase: Phase 2
Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy
Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy
Enrollment Status: Completed
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drugs: Carfilzomib, Irinotecan
Study Phase: Phase 1/Phase 2
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
Enrollment Status: Unknown
Publish Date: June 12, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Etoposide, Carboplatin
Study Phase: Phase 3
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
A Phase II, Single-center, Open-label Study of Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
Enrollment Status: Withdrawn
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib
Enrollment Status: Terminated
Publish Date: July 18, 2019
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 19, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Enrollment Status: Terminated
Publish Date: November 06, 2018
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations
Enrollment Status: Completed
Publish Date: October 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI
Enrollment Status: Terminated
Publish Date: February 27, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 16 Less Clinical Trials

30 Total Publications

Racialized economic segregation and disparities in non-small cell lung cancer care and outcomes.
Racialized economic segregation and disparities in non-small cell lung cancer care and outcomes.
Journal: CHEST pulmonary
Published: September 25, 2025
Similar Doctors
Advanced in Gastrostomy
Dr. Douglas R. Adkins
Oncology
Advanced in Gastrostomy
Dr. Douglas R. Adkins
Oncology

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (11.7 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Douglas Adkins is an Oncologist in Saint Louis, Missouri. Dr. Adkins is rated as an Elite provider by MediFind in Gastrostomy. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Gastrostomy. Dr. Adkins is currently accepting new patients.

Experienced in Gastrostomy
Dr. Peter Oppelt
Hematology | Oncology
Experienced in Gastrostomy
Dr. Peter Oppelt
Hematology | Oncology

Washington University

150 Entrance Way, St Peters Siteman Cancer C, 
St Peters, MO 
 (10.2 miles away)
636-916-9920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Peter Oppelt is a Hematologist and an Oncologist in St Peters, Missouri. Dr. Oppelt is rated as a Distinguished provider by MediFind in Gastrostomy. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adult Soft Tissue Sarcoma, Laryngeal Cancer, Reconstructive Urology Surgery, and Gastrostomy.

Matthew A. Powell
Experienced in Gastrostomy
Dr. Matthew A. Powell
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Experienced in Gastrostomy
Dr. Matthew A. Powell
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Washington University

660 S Euclid Ave Campus Box, 8064 Department Of Obstetr, 
Saint Louis, MO 
 (11.3 miles away)
314-747-8274
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Powell is a Gynecologic Oncologist and an Oncologist in Saint Louis, Missouri. Dr. Powell is rated as an Elite provider by MediFind in Gastrostomy. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Oophorectomy. Dr. Powell is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baggstrom's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile